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The rapid rise of drug-resistant bacteria is one of the most serious unmet medical needs facing the world.
Despite this increasing problem of antibiotic resistance, the number of different antibiotics available for
the treatment of serious infections is dwindling. Therefore, there is an urgent need for new antibacterial drugs,
preferably with novel modes of action to potentially avoid cross-resistance with existing antibacterial agents.
In recent years, increasing attention has been paid to bacterial protein secretion as a potential antibacterial
target. Among the different protein secretion pathways that are present in bacterial pathogens, the general
protein secretory (Sec) pathway is widely considered as an attractive target for antibacterial therapy. One of
the key components of the Sec pathway is the peripheral membrane ATPase SecA, which provides the
energy for the translocation of preproteins across the bacterial cytoplasmic membrane. In this review, we
will provide an overview of research efforts on the discovery and development of small-molecule SecA inhib-
itors. Furthermore, recent advances on the structure and function of SecA and their potential impact on anti-
bacterial drug discovery will be discussed.Bacterial Resistance and the Need for New Antibiotics
Improper use of antibiotics has led to a widespread increase in
the occurrence of drug-resistant andmultidrug-resistant bacteria
(Chen et al., 2009). Consequently, physicians are increasingly
being faced with infections caused by bacteria for which limited
or no effective antibiotics exist. In terms of high incidence of
infection,morbidity,mortality and resistance factors undermining
standard antibiotic therapy, the most problematic bacterial
pathogens include methicillin-resistant Staphylococcus aureus
(MRSA), vancomycin-resistant Enterococci, and extended-
spectrum b-lactamase–producing gram-negative bacteria
(Escherichia coli, Pseudomonas aeruginosa, Acinetobacter
baumanii, and Klebsiella pneumonia, among others) (Nordmann
et al., 2007; Shorr, 2009; Woodford and Livermore, 2009). Infec-
tions caused by antibiotic-resistant bacteria are not only associ-
ated with higher mortality rates, but also result in prolonged
hospital stays and increased healthcare costs (Slama, 2008).
Paradoxically, as the problems accompanying antibiotic resis-
tance increase, the number of different antibiotics available to
treat serious infections is dwindling. In the last 30 years, only
three completely new classes of antibiotics have been intro-
duced: the oxazolidinones (linezolid) (Herrmann et al., 2008),
the cyclic lipopeptides (daptomycin) (Robbel and Marahiel,
2010), and a natural product isolated from Streptomyces
platensis (platensimycin) (Lu and You, 2010). The reasons behind
the decreasing number of antibiotics reaching the market are
complex, but are partly a result of decreased research and
development activities in the pharmaceutical industry (Spellberg
et al., 2008). As a consequence, there are only a handful of anti-
biotics in the drug development pipeline, most of them being
analogs of existing classes of antibacterials with improved prop-
erties (Devasahayam et al., 2010). Hence, there is an urgent needChemistry & Bifor new antibacterials, preferably from new structural classes
and with novel modes of action to avoid cross-resistance with
existing antibiotics (Payne, 2008).
In the framework of the search for new antibacterial therapies
to combat infections caused by multidrug-resistant bacteria,
new antibiotic targets are currently being proposed and evalu-
ated, including components of the bacterial protein secretion
pathways such as SecA (Baron, 2010; Economou, 2001; Marra,
2006) and signal peptidase type I (Rao et al., 2009; Smith et al.,
2011). In this review, we will focus on SecA, a key protein of the
general secretory (Sec) pathway.
The Sec Pathway
General Features of Sec-Dependent Preprotein
Translocation
The Sec pathway, together with the twin-arginine translocation
(Tat) pathway, accounts for the majority of protein transport
across the bacterial cytoplasmic membrane (Holland, 2010).
Although the Tat pathway has mostly been implicated in the
transport of folded proteins, the Sec pathway is involved in the
translocation of unfolded preproteins and the insertion of
membrane proteins across or into the cytoplasmic membrane
(Natale et al., 2008). In contrast to the Tat pathway, the Sec
machinery is essential for bacterial viability, making it an attrac-
tive target for antibacterial therapy (Economou, 2001). Moreover,
several components of the Sec pathway are highly conserved
among gram-negative and -positive pathogens but do not
have close structural homologs in humans, making them attrac-
tive candidates for antibacterial drug discovery (Cao and Saier,
2003; Hand et al., 2006).
Secretory proteins that are exported via the Sec pathway are
synthesized at the ribosome as unfolded precursors withology 18, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 685
Figure 1. Schematic Model of Sec-Dependent Preprotein Translocation in Gram-Negative Bacteria
Sec-dependent secretory preproteins (thick black line; the signal peptide is represented as a gray rectangle) are targeted to SecA by the molecular chaperone
SecB (I). Binding of the SecA-preprotein complex to the SecYEG translocation channel (II) and subsequent rounds of ATP binding and hydrolysis (III–V) result in
large conformational changes in SecA that are coupled to the stepwise translocation of the preprotein. When translocation is complete, the signal peptide is
cleaved off by signal peptidase that is present at the periplasmic side of the membrane, leading to the release and folding of the mature protein.
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a secretory preprotein has emerged from the ribosome, it can
be targeted to the SecYEG preprotein-conducting channel in
the cytoplasmic membrane via different pathways. A first target-
ing route involves the molecular chaperone SecB, a secretion-
dedicated chaperone that is present in many gram-negative
bacteria but is absent in gram-positive organisms (Muller et al.,
2000; van Wely et al., 2001). SecB acts by binding to partially
folded precursor proteins, either free in the cytosol or bound to
cytoplasmic SecA (Bechtluft et al., 2010; Crane et al., 2005; Ran-
dall et al., 2005; Randall and Henzl, 2010; Suo et al., 2011; Zhou
and Xu, 2003). The interaction with SecB keeps the newly
synthesized preproteins in a more or less unfolded conformation
that allows them to pass through the translocation channel of the
Sec pathway. However, not all secretory proteins depend on
SecB. These preproteins are targeted to the Sec translocase
by SecA or by general cytosolic chaperones such as GroEL
and/or DnaK, which can substitute partially for SecB under
certain conditions (Bochkareva et al., 1998; Lecker et al.,
1989). A second, SecB-independent targeting route is mediated
by the signal recognition particle (SRP). Secretory preproteins
that are targeted by the SRP pathway are transported to the
Sec translocase in a nascent, ribosome-associated state, which
does not necessarily require an interaction with SecA (Kuhn
et al., 2011; Luirink and Sinning, 2004).
Irrespective of the targeting route, all preproteins eventually
reach the cytoplasmic membrane, where they are transferred
to the translocase. The translocase is a multisubunit membrane
protein complex that consists of the peripheral membrane
ATPase SecA and a preprotein-conducting channel composed
of the integral membrane proteins SecY, SecE, and SecG (du
Plessis et al., 2011). After docking of the preprotein to the trans-
locase complex, the preprotein is translocated through the
SecYEG channel in a stepwise manner, using the energy from
SecA-catalyzed ATP hydrolysis as well as the proton motive686 Chemistry & Biology 18, June 24, 2011 ª2011 Elsevier Ltd All rigforce. Following preprotein translocation, the signal peptide is
cleaved off by an exocytoplasmic signal peptidase, which results
in the release and folding of the mature protein.
SecA, a Central Component of the Sec Pathway
Structure and domain organization. The domain organization
of SecA has been revealed by biochemical and biophysical
analyses and by the elucidation of several SecA structures
from different species. Of the six published SecA crystal struc-
tures, five are dimeric (Hunt et al., 2002; Papanikolau et al.,
2007; Sharma et al., 2003; Vassylyev et al., 2006; Zimmer
et al., 2006), and one is monomeric (Osborne et al., 2004). The
protomers of each dimer all have a similar structure, but surpris-
ingly the position of each protomer relative to one another is
unique (Sardis and Economou, 2010). Although most dimers
have an antiparallel orientation, the structure from Thermus ther-
mophilus revealed a parallel conformation. At the moment it is
unclear which of these structures, if any, represents a physiolog-
ical relevant state. One possibility raised by the structural studies
is that some of the dimeric structures are the result of artifacts
arising from crystal packing and the harsh crystallization condi-
tions used (Hunt et al., 2002; Papanikolau et al., 2007; Sardis
and Economou, 2010; Sharma et al., 2003; Vassylyev et al.,
2006; Zimmer et al., 2006). However, cross-linking and directed
cysteine mutagenesis studies have demonstrated that the
parallel and two antiparallel forms also exist in solution (Jilaveanu
and Oliver, 2006; Or et al., 2005; Vassylyev et al., 2006; Zimmer
et al., 2006). Moreover, it has been demonstrated that unli-
ganded SecA exists in solution in a monomer-dimer equilibrium
with a KD in the nanomolar or micromolar range, depending on
the salt concentration (Das et al., 2008; Woodbury et al., 2002;
Wowor et al., 2011). This finding suggests that SecA is mostly
dimeric in vivo, because the cellular SecA concentration is esti-
mated to be up to 8 mM (Or et al., 2002). However, the precise
oligomeric state of SecA as it functions during the translocation
cycle is still a matter of debate. Although some lines of evidencehts reserved
Figure 2. Three-Dimensional Structure of the E. coli SecA Monomer
Color coding of SecA domains: NBD, dark blue; IRA2, cyan; PBD, orange;
IRA1, green; SD, red; HWD, pink; and CTL (first 4 residues), black. The bound
ATPmolecule is shown in ball representation (red). The figure was created with
ICM-browser (Molsoft LLC), using the coordinates of the ecSecA NMR
structure (Gelis et al., 2007) (PDB code 2VDA).
Chemistry & Biology
Reviewsupport the notion that monomeric SecA can function in protein
export (Alami et al., 2007; Benach et al., 2003; Duong, 2003; Or
et al., 2005; Or et al., 2002; Or and Rapoport, 2007; Zimmer et al.,
2008), several studies indicate that complete dissociation of the
two protomers is not essential for translocation (Akita et al.,
1991; Bu et al., 2003; Das et al., 2008; de Keyzer et al., 2005;
Jilaveanu and Oliver, 2006; Jilaveanu et al., 2005; Karamanou
et al., 2005; Mao et al., 2009; Randall et al., 2005; Shin et al.,
2006; Wang et al., 2008).
In each of the SecA crystal structures, the protomer structures
are very closely related. Each SecA protomer can be subdivided
into several structural domains (Figure 2). The ‘‘DEAD’’ motor,
the catalytic core of SecA, consists of two domains: the nucleo-
tide binding domain (NBD) and the intramolecular regulator of
ATPase activity 2 domain (IRA2). Both domains are structurally
homologous to the RecA-like nucleotide binding folds that are
also found in DNA/RNA helicases (Tanner and Linder, 2001). At
the interface of the NBD and the IRA2 domain is a large cleft,
which constitutes the active site of SecA.
The substrate specificity of SecA is conferred by two unique
domains that distinguish SecA from other helicases: the prepro-
tein binding domain (PBD) and the C-terminal domain. The PBD
protrudes from the NBD and contains an antiparallel b strand
(stem) and a bilobate globular domain (bulb). The stem and
bulb region are located at the bottom of a large cleft that has
been implicated in preprotein binding (Cooper et al., 2008;
Papanikou et al., 2005). The C-terminal domain is composed of
four substructures: the helical wing domain (HWD), a long
a-helical scaffold domain (SD), the intramolecular regulator of
ATP hydrolysis (IRA1), and a C-terminal linker (CTL) (Figure 2).
Model for SecA-mediated preprotein translocation. On the
basis of the currently available biochemical, structural, and
biophysical data, a model for SecA-mediated preprotein translo-
cationhasbeenproposed. In thismodel, SecA is a solubleprotein
that partitions equally between cytoplasmic and membrane-
associated states (Cabelli et al., 1991). The ATPase activity ofChemistry & BiSecA is regulated by a complex allosteric mechanism that
controls the intramolecular interaction of the NBD and IRA2
domains, thereby regulating the opening and closure of the
nucleotide-binding cleft and modulating the ATPase activity (Lill
et al., 1990; Robson et al., 2009; Sianidis et al., 2001). In the
absence of translocation ligands, the release of ADP is the main
rate-limiting step of SecA catalysis (Fak et al., 2004). Conse-
quently, cytoplasmic SecA is predominantly in an ADP-bound
conformation with low ATPase activity. This compact, high-
affinity ADP state is characterized by strong intramolecular inter-
actions between the NBD and IRA2 domains and has low affinity
for membranes and the SecYEG complex (Fak et al., 2004; Hunt
et al., 2002). Binding to SecYEGand themembrane incurs a loos-
eningof these interactions, resulting in an increased rate of nucle-
otide exchange and amarginal stimulation of the intrinsic ATPase
activity (‘‘membrane ATPase’’). In addition, SecYEG binding to
the DEADmotor and C-terminal domain of SecA triggers confor-
mational changes at the interface of the IRA1, PBD, and CTL
domains, leading to an increased affinity for signal peptides.
Binding of the signal peptide to the PBD-NBD interface changes
the conformation of the bulb region, which facilitates trapping of
mature preprotein domains (Baud et al., 2002; Gouridis et al.,
2009; Zimmer and Rapoport, 2009). This binding relieves the
C-terminal domain–mediated suppression, which in turn results
in a substantial increase of the ATPase activity (‘‘translocation
ATPase’’) and opening of a highly conserved salt bridge (termed
Gate 1) at the base of the DEAD motor (Karamanou et al., 2007).
This leads to IRA2 detachment from the NBD, which renders the
DEADmotor in a loose state with decreased affinity for ADP (Kar-
amanou et al., 2007; Keramisanou et al., 2006). The release of
ADP affects the conformation of the PBD (with its preprotein
bound) (Ding et al., 2003; Keramisanou et al., 2006; Papanikou
et al., 2005) and results in SecB release (Fekkes et al., 1997).
Subsequent binding of ATP at the nucleotide-binding cleft
induces additional conformational changes that facilitate deeper
insertion of SecA into the membrane and drive the coinsertion of
preprotein segments of 20–30 amino acids (Schiebel et al., 1991).
Next, hydrolysis of ATP causes a partial release of the preprotein
into the SecYEG channel (Osborne and Rapoport, 2007) and
tightens the NBD-IRA2 interaction. These local conformational
changes in the DEAD motor domain are transmitted to the
C-terminal domain and trigger reassociation of both domains
(Vrontou et al., 2004). This compact, ADP-bound state enables
SecA to de-insert from themembrane, which allows a new round
of ATP binding and catalysis (de Keyzer et al., 2003).
SecA as an Antibacterial Target
A potential drug target should fulfill several criteria in order to be
considered for successful chemotherapeutic intervention. In
addition to being essential for bacterial growth, it should be
conserved across a range of relevant pathogens and ideally
should have no close human homologs. Other desirable features
of the drug target include the presence of ligand-binding pockets
that are druggable by small molecules and the availability of
functional assays that allow high-throughput screening of large
compound libraries. As will be illustrated in the following para-
graphs, SecAmeets each of these criteria, making it an attractive
target for the development of novel antibacterials.
SecA is essential for cell viability. An important criterion for the
selection of a gene product as an antibacterial target is that it isology 18, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 687
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2004). Several studies have identified SecA as an essential gene
in both gram-negative and -positive organisms. First, a number
of conditionally lethal SecA amber mutants have been isolated
in a variety of bacterial species, including the gram-negative
and -positive model organisms E. coli and Bacillus subtilis
(Kang and Shapiro, 1994; Oliver and Beckwith, 1981; Sadaie
and Kada, 1985). Further characterization of these mutant
strains has demonstrated that the SecA amber mutation is sup-
pressed by temperature-sensitive amber suppressors, which
restore bacterial growth at the permissive temperature (30C).
At the nonpermissive temperature (42C), however, the SecA
mutation leads to defective protein secretion and cell division,
ultimately resulting in cell death (Oliver and Beckwith, 1981;
Sadaie and Kada, 1985).
The essentiality of the SecA protein was further demonstrated
via a protein knockout technique (Benson et al., 2003). Peptides
that bind specifically to purified E. coli SecA (ecSecA) were
isolated from phage display libraries and subsequently were
expressed in E. coli. Expression of the selected peptides
resulted in bacterial growth inhibition, whereas the expression
of scrambled peptides had no effect. Moreover, growth inhibition
could be relieved by concurrent overexpression of the SecA
gene but not by coexpression of an irrelevant gene, indicating
that the observed inhibition was due to a specific interaction
between SecA and the expressed peptide.
The SecA gene was also found to be essential in
Corynebacterium glutamicum (Rigel and Braunstein, 2008) and
several pathogens, such asMycobacterium species (Braunstein
et al., 2001), Streptococcus pneumoniae (Akerley et al., 1998),
Staphylococcus aureus (Forsyth et al., 2002), and Burkholderia
pseudomallei (Moir et al., 2008).
SecA is a conserved protein with no close human homolog.
The availability of the human genome sequence and the
increasing number of complete microbial genome sequence
data has led to the development of new approaches for the
identification of promising bacterial drug targets. One such
strategy is based on a subtractive genomics approach, in which
the subtraction dataset between the host and pathogen genome
provides information for a set of genes that are likely to be essen-
tial to the pathogen but absent in the host (Barh et al., 2009).
Thus, comparison of essential bacterial genes against the human
genome permits the identification of bacterial gene products that
are not present or are nonhomologous to the human host. Such
gene products can be considered as attractive antibacterial
targets because drugs targeting these proteins will likely have
a reduced toxicity to the host. Subtractive genomics approaches
have been successfully used to identify drug targets in many
bacterial species, such as Pseudomonas (Sakharkar et al.,
2004), Mycobacterium (Anishetty et al., 2005), Clostridium
(Chhabra et al., 2010) and Burkholderia (Chong et al., 2006). In
these in silico studies, the SecA gene was found to be essential
and unique to bacteria, suggesting that it may represent an
attractive therapeutic target.
Is SecA a druggable target?. In addition to being essential for
bacterial growth and having no close functional human homolog,
an antibacterial drug target must also be druggable—that is, it
should possess the propensity to bind druglike small molecules
with high affinity. It is estimated that 60% of small molecule688 Chemistry & Biology 18, June 24, 2011 ª2011 Elsevier Ltd All rigdrug discovery projects fail in the hit-to-lead stage because
the biological target is found to be not druggable (Brown and
Superti-Furga, 2003).
One approach for evaluating protein druggability is on the
basis of sequence and structural homology to known therapeutic
drug targets (Watson et al., 2005). Several inhibitors of super-
family 2 RNA helicases are currently in clinical development
(Dropulic and Cohen, 2010), indicating that it is feasible to target
members of this enzyme class by small molecules.
Another approach to predict protein druggability relies on the
identification of binding pockets of suitable size, shape, and
hydrophobicity to accommodate druglike molecules (Hajduk
et al., 2005). Many such methods have been developed and
validated using training sets of ligand-binding sites extracted
from the Protein Data Bank (PDB) (Perot et al., 2010). To identify
putative ligand-binding pockets on SecA, we have analyzed the
molecular surface of the ecSecA NMR structure (Gelis et al.,
2007) using PocketFinder (An et al., 2005). The PocketFinder
algorithm, which is based on a transformation of the Lennard-
Jones potential, not only detects the location of the binding
pocket but also predicts envelopes representing the shape and
size of putative ligand-binding pockets. The size and character
of the predicted cavities can help to estimate the druggability
of a pocket, because druggable pockets tend to be deep, hydro-
phobic, and of limited size (typically between 200 and 600 A˚3).
Several ligand-binding pockets with appropriate shape descrip-
tors (surface area and volume) were identified on the SecA
surface (data not shown). This finding not only indicates that
SecA is amenable to targeting by small molecules but also
suggests that different strategies can be pursued for the design
of potent and selective SecA inhibitors. For example, it is
conceivable that SecA inhibitors targeting regions other than
the active site can be discovered, which may serve as lead
compounds for the development of antibacterials with a com-
pletely novel action mechanism.
One of the factors affecting the druggability of a bacterial
target is its accessibility for small molecules. This can be a partic-
ular problem with cytoplasmic targets such as SecA, because
antibiotics that target these proteins have to cross at least one
bacterial membrane. Cell impermeability issues are more often
encountered with gram-negative bacteria, because gram-posi-
tive organisms possess a permeable cell wall that usually does
not restrict the penetration of antibacterials (Lambert, 2002).
The outer membrane of gram-negative bacteria is an addi-
tional barrier that excludes large molecules from entering the
cell. However, small polar molecules, including many antibiotics,
can enter the cell through aqueous protein channels formed by
transmembrane proteins (porins) (James et al., 2009). Further-
more, most antibiotics show some hydrophobicity, which allows
them to diffuse across the lipid bilayers of the cytoplasmic
membrane.
Screening assays for the discovery of SecA inhibitors. An
important aspect of theearlydrugdiscoveryprocess is thedesign
and implementation of high-throughput functional assays that
allow the cost-effective screening of large compound libraries
to identify novel drug candidates. Therefore, it is of crucial impor-
tance that the activity of the target protein canbemonitoredusing
assays that are compatible with high-throughput screening
formats. Several in vitro assays with purified components havehts reserved
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assay to measure the intrinsic, membrane, and preprotein-stim-
ulated ATPase activities of SecA is based on themalachite green
colorimetricmethod for the detection of free inorganic phosphate
(Gouridis et al., 2010; Lanzetta et al., 1979; Mitchell and Oliver,
1993). Althoughmalachite green assays have proven to be useful
for high-throughput screening, the SecA ATPase activity assays
are not readily adaptable to automated high-throughput
screening for several reasons. A major disadvantage of the
membrane and translocation ATPase assays is the complexity
of the assay system, which requires the use of membrane prepa-
rations (inner membrane vesicles or proteoliposomes containing
functional SecYEG complexes) and unfolded preproteins.
Because many compounds in small-molecule libraries tend to
be hydrophobic, it can be expected that a large proportion of
the screened molecules will bind to the membrane and possibly
also affect membrane integrity. This would result in many false
positives, similar to the high number of membrane-damaging
molecules among the hits that were selected in an in vivo high-
throughput screen to detect secretion inhibitors (Alksne et al.,
2000). An alternative to circumvent the difficulties associated
with the use of membrane components is the use of a high-
throughput screen assay to measure the inhibition of the intrinsic
SecA ATPase activity. However, because the ATPase activity of
SecA is suppressed by several intramolecular mechanisms in
the absence of translocation ligands, such screening assays
would suffer from a poor signal-to-noise ratio and reduced sensi-
tivity. To address this problem,we havedeveloped an automated
high-throughput screen assay in 384-well format using an
ecSecA mutant with elevated intrinsic ATPase activity (Segers
et al., 2011). The mutated residue, Trp775, is located at the inter-
face of the SD and IRA1 domains, which are important for the
intramolecular regulation of the SecA ATPase activity (Vrontou
et al., 2004).Mutation of the bulky, hydrophobic Trp775 side chain
for a short alanine side chain results in a weakened IRA1/SD
interaction, which partially relieves the IRA1-mediated suppres-
sion and causes an approximately 5-fold increase in intrinsic
ATPase activity compared to wild-type ecSecA (Keramisanou
et al., 2006; Vrontou et al., 2004). Hopefully, our developed
high-throughput screen assay is only a first progression in the
development of detection methods that will facilitate the
screening of large chemical libraries to discover SecA inhibitors.
With respect to this, it should be noted that the SecA HTS assay
monitors the inhibition of intrinsic ATP hydrolysis and therefore
essentially active site inhibitors will be identified. In addition to
nucleotides, however, SecA interacts with many other ligands
such as the cytoplasmic membrane, the SecYEG translocation
channel, molecular chaperones, and unfolded preproteins. This
offers additional opportunities for the development and design
of SecA inhibitors with different action mechanisms. Neverthe-
less, high-throughput screen methods to discover inhibitors
that target the interaction of SecA with its nonnucleotide ligands
still have to be developed. Fluorescence and surface plasmon
resonance (SPR) techniques have already been applied to study
the interaction of SecA with signal peptides, preproteins,
SecYEG, and membranes (de Keyzer et al., 2003; Kusters et al.,
2010; Musial-Siwek et al., 2005). Because both methods are
compatible with high-throughput screening, they may prove
promising tools for the development of next-generation high-Chemistry & Bithroughput screen assays that are optimized to discover SecA
inhibitors with different action mechanisms.
Targeting the Preprotein Translocase Motor
Small-Molecule Inhibitors of SecA
To date, only a few small-molecule inhibitors of SecA have been
described. The antibacterial activity of sodium azide, the first
known SecA inhibitor, was already reported at the end of the
19th century (Loew, 1891). One hundred years after this
discovery, it was demonstrated that sodium azide effectively
inhibits Sec-dependent protein translocation in vitro and in vivo
(Oliver et al., 1990). Mutations conferring sodium azide resis-
tance in E. coli and B. subtilis were found to occur primarily in
the SecA gene, indicating that SecA is the major cellular target
of sodium azide (Klein et al., 1994; Nakane et al., 1995; Oliver
et al., 1990). Sodium azide is known to inhibit the translocation
ATPase activity of E. coli and B. subtilis SecA (IC50, 5 mM for
ecSecA), but it does not affect the intrinsic, preprotein-indepen-
dent ATPase activity (Nakane et al., 1995; Oliver et al., 1990).
Binding of sodium azide to SecA does not block nucleotide
binding at the active site and has also no effect on the formation
of the compact, protease-resistant form of SecA in the presence
of ATP or the poorly hydrolyzable ATP analog ATP-g-S (van der
Wolk et al., 1997). Furthermore, azide promotes the formation of
a protease-resistant 30-kDa fragment in limited trypsinolysis
experiments (Eichler et al., 1998; van der Wolk et al., 1997).
The formation of this fragment is induced by ATP and preproteins
and has been correlated with SecA membrane insertion. On the
other hand, it was demonstrated by pulse-chase experiments
that azide blocks membrane de-insertion of SecA, which
requires the hydrolysis of ATP (Economou et al., 1995; van der
Wolk et al., 1997). Taken together, it can be concluded that azide
traps SecA in a transitional state during the translocation
reaction by stabilizing its membrane-inserted, ADP-bound state.
In addition to SecA, azide also inhibits a number of other
ATPases, including mitochondrial F-ATPases. In the crystal
structure of the ternary complex of F1-ATPase with ADP and
azide, the azide anion interacts with the b-phosphate of ADP
and several active site residues (Bowler et al., 2006). The pres-
ence of the azide anion brings the side chains of two catalytically
essential amino acids closer to the nucleotide, creating a tighter
binding interface for the ADP molecule and thereby stabilizing
the ADP-bound state. Because SecA binds adenine nucleotides
with a very similar geometry to F1-ATPase (Hunt et al., 2002), it
can be expected that azide inhibits SecA via a comparable
mechanism. This would also explain how azide stabilizes the
membrane-inserted, ADP-bound conformation of SecA.
An in vivo, high-throughput screen using a SecA-LacZ fusion
reporter construct in E. coliwas used by researchers fromWyeth
to discover Sec-dependent secretion inhibitors (Alksne et al.,
2000). The assay is based on the observation that SecA transla-
tion is autogenously regulated in response to changes in secre-
tion levels (Oliver and Beckwith, 1982). Under normal secretion
conditions, SecA inhibits its own expression by binding to
SecA mRNA. In contrast, inhibition of secretion leads to dissoci-
ation of the SecA-mRNA complex and subsequent up-regulation
of SecA translation (Schmidt and Oliver, 1989). Although this
whole-cell screening system has resulted in the identification
of several molecules that induced SecA expression (Figure 3,ology 18, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 689
Figure 3. Selected Examples of SecA Inhibitors
1: 2-benzyl-1-[1-[4-[4-[4-[1-[(N’-benzylcarbamimidoyl)dia-
zenyl]ethyl]phenyl]piperazin-1-yl]phenyl]ethylimino]guani-
dine (Alksne et al., 2000); 2: CJ-21058 (Sugie et al., 2002);
3: pannomycin (Parish et al., 2009); 4: SEW-05929 (Li et al.,
2008); 5: HTS-12302 (Li et al., 2008); 6: 2,20-(a,a0-xylene)
bis(sulfanediyl)bis-4-oxopyrimidine (Chenet al., 2010);7: 1-
(4-(5-amino-7-(4-fluorophenyl)thiazolo[4,5-d]pyrimidin-2-
yl)piperazin-1-yl)-2-(4-fluorophenoxy)ethanone (Janget al.,
2010).
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secretion, all hit molecules were found to have deleterious
effects on membranes (Alksne et al., 2000).
The first natural product inhibitor of SecA, CJ-21058 (Figure 3,
compound 2), was isolated from the fermentation broth of an
unidentified fungus (Sugie et al., 2002). CJ-21058 was found to
be an analog of the fusarium toxin equisetin, a fungal metabolite
first isolated from the white mold Fusarium equiseti (Burmeister
et al., 1974). Equisetin derivatives, which fall into the acyl tetra-
mic acid class of natural products, exhibit a wide range of biolog-
ical properties, including antibiotic and HIV inhibitory activity,
cytotoxicity, and mammalian DNA binding (Schobert and
Schlenk, 2008). CJ-21058 was found to inhibit the translocation
ATPase activity of SecA (IC50, 15 mg/ml) and also showed
good inhibitory activity against multidrug-resistant S. aureus
and Enterococcus faecalis (MIC, 5 mg/ml), but not against
Streptococcus pyogenes and E. coli (Sugie et al., 2002).
A second natural product inhibitor of SecA was discovered by
an antisense screening strategy, using anS. aureus strain with an
inducible SecA antisense construct (Parish et al., 2009). A library
containing over 115,000 natural product extracts was screened
against this SecA antisense strain and a vector control strain
using a high-throughput two-plate whole-cell differential690 Chemistry & Biology 18, June 24, 2011 ª2011 Elsevier Ltd All rights reservedsensitivity screen. By this strategy, a new cis-
decalin secondary metabolite from Geomyces
pannorum, a fungal strain isolated from leaf
litter, was identified as a SecA inhibitor. The iso-
lated compound, pannomycin (Figure 3, com-
pound 3), showed very weak antibacterial
activity against the gram-positive organisms
S. aureus (MIC, 1.4 mM), E. faecalis (MIC,
1.4 mM), and B. subtilis (MIC, 0.4 mM), but no
detectable activity against S. pneumoniae,
Haemophilus influenzae, E. coli, and Candida
albicans (Parish et al., 2009). The structure of
pannomycin is closely related to that of cissetin,
a tetramic acid derivative with activity against
MRSA (MIC, 10 mM) (Boros et al., 2003).
Remarkably, both molecules contain a quater-
nary carbon atom at position C-6, a feature
that is also present in the SecA inhibitor CJ-
21058. The more potent activity of cissetin and
CJ-21058 may be ascribed to the presence of
a tetramic acid in both structures. Altogether,
the structural similarity between these natural
products suggests that the decalin-tetramic
acid scaffold with a quaternary carbon centerat position C-6 could provide a starting point for the develop-
ment of more potent SecA inhibitors.
The first structure-based approach to discover SecA inhibitors
was based on virtual ligand screening against the E. coli SecA
crystal structure (Li et al., 2008). Initially, around 60,000 commer-
cially available compounds were screened in silico for predicted
binding to the SecA active site. The 31 best-ranked molecules
were then tested for in vitro inhibition of the intrinsic ATPase
activity of the isolated N68 domain of SecA, which contains the
DEAD motor and PBD. Using this approach, two SecA inhibitors
were identified with modest activity (IC50, 100 mM) (Figure 3,
compounds 4 and 5) (Chen et al., 2010; Li et al., 2008). Chemical
optimization of these two hits has resulted in the discovery of
substituted thiouracils with improved inhibitory activity (IC50,
20–60 mM for inhibition of the intrinsic ATPase activity of full-
length SecA; Figure 3, compound 6) (Chen et al., 2010).
A high-throughput screening assay using a SecA mutant with
elevated intrinsic ATPase activity was used to screen a diverse
compound library of 27,000 molecules (Segers et al., 2011).
Several inhibitors of the intrinsic, membrane and translocation
ATPase activity of SecAwere identified with IC50 values between
50 and 150 mM. Furthermore, it was shown that these hit mole-
cules did also block the in vitro translocation of the model
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taining overexpressed SecYEG. The inhibitors identified in this
HTS study belong to different chemical classes, including the
pyrrolo-pyrimidines and nipecotic acid derivatives.
Finally, synthesis and screening of a library of thiazolo[4,5-d]
pyrimidine derivatives has identified several ATPase inhibitors
of E. coli and S. aureus SecA1 (Jang et al., 2010). Kinetic analysis
of the most potent inhibitor (Figure 3, compound 7) indicated
a mixed-type inhibition, with an inhibition constant of 60 mM for
inhibition of the translocation ATPase activity of saSecA1.
SecA Inhibitors and the Bacterial Cellular Response
Because SecA is the essential motor protein that provides the
energy required for the Sec-dependent translocation of prepro-
teins across the cytoplasmic membrane, it can be anticipated
that SecA inhibition will result in the accumulation of unfolded
preproteins in the bacterial cytoplasm. Several studies have
indeed demonstrated the intracellular accumulation of prepro-
teins upon SecA inhibition (Doerrler and Raetz, 2005; Newitt
and Bernstein, 1998; Oliver and Beckwith, 1982; Wild et al.,
1993). It has been demonstrated that the accumulation and
aggregation of unfolded proteins in the bacterial cytoplasm trig-
gers a cellular stress response (Sabate et al., 2010; Wild et al.,
1993). This response involves an increase in the levels of heat-
shock proteins and chaperones, which are capable of repairing
protein damage by degrading the unfolded, toxic protein aggre-
gates or by preventing protein misfolding. However, if these
rescue systems fail, for example because of an overload of
unfolded or misfolded proteins, the accumulation of insoluble
protein aggregates ultimately leads to cell death (Sabate et al.,
2010).
Additional evidence that inhibition of SecA will have a bacteri-
cidal effect comes from a recent study on the action mechanism
of chloramphenicol and tetracycline. It is widely accepted that
both antibiotics target protein synthesis by specifically binding
to the bacterial ribosome (Pioletti et al., 2001; Schlunzen et al.,
2001), but recently another actionmechanismof thesemolecules
has been proposed (Breukink, 2009; van Stelten et al., 2009).
Both antibiotics stop the translation of messenger RNA, leaving
incomplete polypeptides that are firmly attached to ribosomes.
Ribosomes bearing incomplete proteins with a Sec signal
peptide are targeted to the cytoplasmic membrane, where they
cause a physical jamming of the SecYEG translocation channel.
Obstruction of the SecYEG channel results in the cytoplasmic
accumulation of unfolded preproteins, which triggers a stress
response (vanStelten et al., 2009). This cell response ismediated
by the two-component Cpx regulatory system and leads to the
proteolytic digestion of SecY by the protease FtsH. The suicidal
nature of SecY destruction reflects the observation that SecY is
required for the incorporation of newly synthesized SecY in the
membrane (Akiyama and Ito, 1989), and further supports the
notion that blocking Sec-dependent protein translocation is
a valid strategy for antibacterial intervention.
Future Strategies for the Discovery of SecA Inhibitors
The majority of the SecA inhibitors identified so far are able to
block the intrinsic ATPase activity, indicating that these mole-
cules compete with ATP binding or prevent ATP hydrolysis by
binding to an allosteric site on SecA. However, considering the
fact that SecA plays a pivotal role in protein translocation andChemistry & Bitherefore has to interact with a plethora of ligands, additional
strategies for the development of novel SecA inhibitors may be
explored. Recently, a crystal structure of SecA in complex with
the SecYEG translocation channel and an NMR solution struc-
ture of a SecA-signal peptide complex became available (Gelis
et al., 2007; Zimmer et al., 2008). These high-resolution struc-
tures do not only provide a basis for determining the mechanistic
details of the preprotein translocation process, but also offer
opportunities for the rational design of inhibitors that target
the interaction of SecA with the SecYEG complex or with
preproteins.
The SecA-SecYEG Interaction
Despite the fact that SecA has been extensively studied and
crystal structures of SecA in various conformational states are
available (Hunt et al., 2002; Sharma et al., 2003; Vassylyev
et al., 2006; Zimmer et al., 2006), structural information about
its association with the SecYEG translocation channel is limited.
In recent years however, substantial progress has been made
toward a better understanding of the SecA-SecYEG interaction.
The first detailed view of a bacterial core translocase was
provided by the high-resolution crystal structure of the archaeal
SecYEb complex of Methanococcus jannaschii (Van den Berg
et al., 2004). The structure reveals that the 10 transmembrane
segments (TM) of the main subunit of the complex, SecY, are
arranged like a clamshell in which the two halves (TM 1–5 and
TM 6–10) are connected by a periplasmic loop between TM5
and TM6 (Figures 4A and 4B). The second subunit of the
complex, SecE, has a single highly tilted TM domain that tracks
across one face of the complex and makes extensive contacts
with SecY (Figure 4B). A surface-exposed amphiphatic helix of
SecE runs parallel to the cytoplasmic face of the membrane.
The small b subunit was identified as a single helix on the outside
of the complex, consistent with the observation that it is not
essential for the major activity of the protein channel.
Different techniques have been used to define the interaction
of SecA with the SecYEG complex and to map the relevant
binding sites (Karamanou et al., 2008; Mori and Ito, 2006; Rob-
son et al., 2007; van der Sluis et al., 2006). By a combination of
peptide scanning and cysteine-directed cross-linking, two func-
tionally important regions in SecY that are involved in the SecA
interaction were identified (van der Sluis et al., 2006). The first
region comprises several residues in the cytoplasmic loop
between TM8 and TM9, whereas the second interaction site is
part of TM4 of SecY that is buried in the membrane region of
SecYEG (Figures 4A and 4B). On the basis of an in vivo site-
directed cross-linking approach, a dynamic and function-related
interaction between SecA and the C-terminal cytoplasmic region
(Figures 4A and 4B) of SecY was proposed (Mori and Ito, 2006).
In the same study, cytoplasmic loops 4 and 5 of SecY were put
forward to provide constitutive binding sites for SecA. A
synthetic peptide-binding array based on the cytosolic regions
of SecY and SecE identified regions in the C4 and C5 loops of
SecA as binding partners for SecA (Robson et al., 2007). An
extensive study using peptide binding arrays, thermodynamic
quantification, mutagenesis, and functional assays have map-
ped the SecA interaction sites to five major binding regions in
SecYEG (Karamanou et al., 2008). With the exception of two
minor sites, all the identified SecA-binding sites in this study
were localized at the cytoplasmic side of SecY and SecE.ology 18, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 691
Figure 4. Membrane Topology of E. coli SecY and Interaction of SecA with the SecYEG Complex
(A) Transmembrane domains (TM) and cytoplasmic loops (C) are numbered starting from the N-terminal end of the SecY protein. Transmembrane regions and
cytoplasmic loops interacting with SecA are indicated with arrows.
(B) The crystal structure of Thermotogamaritima SecA (gray) in complex with SecYEG (black) is shown (PDB code 3DIN). Cytoplasmic loopsmaking contacts with
SecA are indicated in red. The SecA helix-two-helix finger is shown in cyan, ATP in ball representation (orange).
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Figure 5. Open and Closed Conformation of SecA
and Potential Preprotein-Binding Sites in SecA
(A) The open (PDB code 1TF5) and closed (PDB code
1M6N) conformation of B. subtilis SecA are shown in
ribbon representation. Color coding of SecA domains:
NBD, dark blue; IRA2, cyan; PBD, purple; and IRA1, SD,
and HWD, green. Preprotein binding grooves 1 and 2 are
indicated by the Roman numerals I and II, respectively.
(B) The NMR structure of E. coli SecA (gray surface) in
complex with the LamB signal peptide (orange ball-and-
sticks) is shown (PDB code 2VDA). The two hydrophobic
pockets in groove 1 that are discussed in the text are
represented as green and purple surfaces. The potential
signal peptide binding region proposed by Musial-Siwek
et al. (2007) is shown as a cyan surface. The b strand
region in groove 2 that has been implicated in preprotein
binding is represented as a red surface.
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interaction were confirmed recently by the elucidation of
the crystal structure of the SecA-SecYEG complex from
Thermotoga maritima (Figure 4B) (Zimmer et al., 2008). The
structure shows that the flat SecA molecule is oriented approx-
imately parallel to the plane of the membrane, creating an exten-
sive binding interface with SecYEG. In line with the available
functional data, the most crucial interactions occur between
the C4 and C5 loops of SecY and the PBD of SecA. Other impor-Chemistry & Biology 18, June 24tant contacts are made by the SD of SecA,
which interacts with the SecG loop, the C2
loop, and the C-terminal tail of SecY. Minor
interactions also occur between NBD1 of
SecA and SecG, whereas IRA2 is not involved
in SecYEG binding. Remarkably, the two-helix
finger of the SD is inserted deeply into the
cytoplasmic funnel of SecY, suggesting an
important role of this substructure in protein
translocation. This was confirmed later bymuta-
genesis and cross-linking studies, which have
demonstrated that the tip of the two-helix finger
interacts with the preprotein during transloca-
tion (Zimmer and Rapoport, 2009). On the basis
of these functional and structural data, it was
proposed that the helix-finger of SecA moves
up and down during the ATP hydrolysis cycle
and pushes the polypeptide into the SecY
channel (Zimmer et al., 2008; Zimmer andRapo-
port, 2009).
The SecA-Preprotein Interaction
The available high-resolution structures of SecA
show that SecA can adopt at least two distinct
conformational states (Hunt et al., 2002; Os-
borne et al., 2004; Papanikolau et al., 2007;
Sharma et al., 2003; Vassylyev et al., 2006;
Zimmer et al., 2006; Zimmer et al., 2008). In
the closed conformation, the PBD and HWD
are in direct contact with each other, whereas
in the open conformation, the PBD has been
rotated toward IRA2 by about 80 (Figure 5A)
(Osborne et al., 2004). This rigid body move-
ment of the PBD creates two deep grooves on
the SecA surface. The first groove is formedbetween the PBD, HWD, and HSD, whereas the second groove
is created at the interface of the PBD and IRA2. Both grooves
have been proposed as potential preprotein-binding sites on
the basis of functional and structural data.
Groove 1 was initially suggested as a potential polypeptide-
binding site on the basis of the crystal structure of B. subtilis
SecA in a monomeric, open conformation (Figure 5A) (Osborne
et al., 2004). Two large pockets in the groove have been
proposed to accommodate the side chains of the bound, 2011 ª2011 Elsevier Ltd All rights reserved 693
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lining the groove have been put forward to interact with the poly-
peptidebackbone. Selective photoaffinity labeling using aphoto-
labeled alkaline phosphatase signal peptide has identified
a potential signal peptide-binding site in tandem with groove 1
(see also Figure 5B) (Musial-Siwek et al., 2007). It has been spec-
ulated that the mature region of the preprotein may extend
C-terminally into groove 1, making backbone contacts with the
charged and polar residues lining the groove. Further evidence
for the involvement of groove 1 in preprotein binding is provided
by an NMR solution structure of ecSecA in complex with a func-
tional signal peptide derived from the LamB porin (Gelis et al.,
2007). The structure shows that the a-helical signal peptide
binds into a large hydrophobic groove that is surrounded by
polar and charged residues. The importance of both hydro-
phobic and electrostatic interactions for strong peptide binding
was confirmed by site-directed mutagenesis and functional
and thermodynamic studies (Gelis et al., 2007).
The second groove, often referred to as ‘‘the clamp,’’ is lined
by two b strands that connect the PBD and NBD1 (Figure 5B).
Several functional studies have suggested that both b strands
play an important role in peptide binding (Auclair et al., 2010;
Baud et al., 2002; Bauer and Rapoport, 2009; Chou and Gier-
asch, 2005; Osborne et al., 2004; Papanikou et al., 2005). Further
support that the clamp is important for preprotein binding is
found in a cocrystal structure of bsSecA and a hydrophilic
peptide that does not resemble a signal peptide (Zimmer and
Rapoport, 2009). The structure shows that the peptide augments
the b sheet at the back of the clamp. The extension of the b sheet
would be sequence-independent, consistent with the fact that
SecA needs to bind a broad range of polypeptide segments.
Targeting the Interaction of SecA with Its Diverse
Ligands
The increasing number of high-resolution structures of SecA in
complex with its different ligands offers opportunities for the
rational design of inhibitors that target the interaction of SecA
with its various binding partners.
A first strategy is to identify inhibitors that prevent ATP binding
and/or hydrolysis. Crystal structures with bound nucleotide
show that the active site of SecA is located at the interface of
NBD and IRA2. The main interactions with the nucleotide take
place in a narrow pocket that contains the classic mononucleo-
tide-binding motif, known as the P loop or Walker motif. Most of
these water-mediated or direct interactions with the nucleotide
are electrostatic in nature. In these structures, the adenine ring
points toward the solvent and makes only a limited number of
contacts with the protein (Hunt et al., 2002; Papanikolau et al.,
2007). Altogether these structural features are not very appealing
for drug discovery. It has been reported that the strength of the
interaction between a protein and a small molecule is highly
correlated with the apolar surface area that is buried upon the
interaction (Olsson et al., 2008). Hence, it may be difficult to
find potent and selective active site inhibitors of SecA, which is
also reflected by the fact that no such inhibitors have been
discovered so far.
An alternative strategy would be to identify compounds that
inhibit protein translocation by preventing the interaction of
SecA with the SecYEG translocation channel or with preprotein.
The identification or design of protein-protein interaction (PPI)694 Chemistry & Biology 18, June 24, 2011 ª2011 Elsevier Ltd All riginhibitors is a far more complicated process than the develop-
ment of molecules targeting active sites or ligand-binding
pockets. First, the contact surfaces involved in PPIs are much
larger compared with those in protein-small molecule interac-
tions (Wells and McClendon, 2007). Another major challenge in
the search for potent PPI inhibitors is the flatness of most protein
interfaces, which implies that only a few cavities are available for
small-molecule binding. Finally, many protein-binding sites turn
out to be structurally adaptive, suggesting that the best binding
site for a small-molecule inhibitor will not always be visible in
a single crystal structure (Wells and McClendon, 2007). Despite
the many challenges associated with the development of PPI
inhibitors, significant progress has been made in the field, as
illustrated by the fact that several candidate PPI inhibitors have
entered clinical trials in recent years (Gao et al., 2010; Richard-
son and Kaye, 2008). This success is mainly due to the existence
of ‘‘hot spots,’’ which are compact regions at many protein-
protein interfaces that are crucial for the high affinity of the inter-
action (Arkin andWells, 2004). The binding of a small molecule to
a subset of hot spot residues is sufficient to interfere with the
interaction of two proteins, making hot spots promising drug
targets (Arkin and Wells, 2004; Wells and McClendon, 2007).
Hot spots on the SecA surface that are important for SecYEG
or preprotein binding have not been identified yet, but the
structures of SecA bound to nucleotide (Hunt et al., 2002),
SecYEG (Zimmer et al., 2008), or a preprotein peptide (Gelis
et al., 2007; Zimmer and Rapoport, 2009) reveal the presence
of several pockets at the SecA surface that may represent
attractive drug targets.
First, computational analysis of the molecular surface of
B. subtilis SecA has revealed the presence of a number of methi-
onine-rich cavities at the interface of NBD1, IRA2, and SD that
may represent a potential binding site for a phospholipid ligand
or a preprotein (Hunt et al., 2002). Although the cavity is only
wide enough to accommodate a hydrocarbon moiety, the high
backbone B factors in this region of the crystal structure suggest
that the cavity could expand upon ligand binding. If this region is
indeed crucial for ligand binding, it may represent an attractive
drug target site because this region is conserved and hydro-
phobic in nature (and therefore likely suited to bind small-
molecules with high affinity).
Another potential drug target is a deep pocket that is formed
by residues of the PBD and the C-terminal domain of SecA. In
the SecA-SecYEG crystal structure, this pocket is occupied
by the C4 loop of SecY, which makes one of the most crucial
interactions with SecA (Figure 4B) (Zimmer et al., 2008).
Other candidate drug target sites on the SecA surface are the
three grooves that were proposed to be involved in preprotein
binding (Gelis et al., 2007; Musial-Siwek et al., 2007; Zimmer
and Rapoport, 2009). The crystal structure of SecA in complex
with a hydrophilic peptide bound to groove 2 indicates that the
two b strands lining the groove interact with the peptide back-
bone by inducing a b strand conformation (Zimmer and Rapo-
port, 2009). The absence of a well-defined, hydrophobic pocket
suggests that groove 2may not represent a very attractive target
for drug discovery. The two other regions in SecA that have been
implicated in preprotein binding, the large groove 1 (Gelis et al.,
2007) and a smaller groove adjacent to it (Musial-Siwek et al.,
2007), appear to be more druggable. Both sites contain severalhts reserved
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cules with high affinity. If these sites are indeed crucial for pre-
protein binding, they may represent promising targets for the
structure-based rational design of small molecules that inhibit
the SecA-preprotein interaction.
Future Perspective
Several high-resolution structures of SecA in its apo form or in
complex with nucleotide or protein ligands have become avail-
able in recent years. These structures have not only increased
our understanding of the molecular mechanism of Sec-depen-
dent protein translocation, but also provide a starting point for
structure-based drug discovery.
The cocrystal structures of SecA with bound nucleotide show
that the adenine ring points toward the solvent and there is little
interaction with the protein. Together with the fact that the ATP-
binding Walker motifs in the active site of SecA are present in
many ATP-binding proteins, it is obvious that it might be difficult
to design selective and potent active site inhibitors of SecA. An
appealing alternative to active site inhibitors is to target the
interaction of SecA with the SecYEG complex or with preprotein.
The recently determined high-resolution structures of SecA with
bound preprotein peptide or in complex with the translocase
channel will certainly aid in the development of such inhibitors.
A future challenge is to obtain high-resolution structures that
provide representative snapshots of the different conformational
states of SecA that are adopted during the ATP hydrolysis cycle.
In combination with additional functional data that provide
detailed information on the mechanism by which the dynamics
and the ATPase activity of SecA are regulated, such structures
may provide the framework for the structure-based design of
allosteric SecA inhibitors. Allosteric binding sites have not faced
the same evolutionary pressure as active sites to accommodate
an endogenous ligand and are therefore more diverse. Conse-
quently, it can be anticipated that more selective SecA inhibitors
may be obtained by targeting allosteric sites.
Finally, the crowningglory of SecA researchwould be the eluci-
dation of the nanomotor in action—that is, bound to the SecYEG
channel and a translocating preprotein polypeptide. Such struc-
ture will undoubtedly offer new opportunities for drug design and
will further advance our understanding of the molecular mecha-
nism of SecA-dependent preprotein translocation.
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